mdl 11939 has been researched along with Anxiety Neuroses in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ásgeirsdóttir, HN; Barrera, MP; Cohen, SJ; Munchow, AH; Stackman, RW; Zhang, G | 1 |
| Cutler, NR; Robinson, RE; Sramek, JJ; Suri, A | 1 |
1 trial(s) available for mdl 11939 and Anxiety Neuroses
| Article | Year |
|---|---|
Efficacy trial of the 5-HT2 antagonist MDL 11,939 in patients with generalized anxiety disorder.
Topics: Adult; Anxiety Disorders; Humans; Male; Piperidines; Serotonin Antagonists; Single-Blind Method | 1995 |
1 other study(ies) available for mdl 11939 and Anxiety Neuroses
| Article | Year |
|---|---|
Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL/6J mice.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Bridged Bicyclo Compounds; Cues; Extinction, Psychological; Fear; Male; Memory; Memory, Episodic; Methylamines; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Nerve Tissue Proteins; Nootropic Agents; Piperidines; Receptor, Serotonin, 5-HT2A; Recognition, Psychology; Reinforcement, Psychology; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists | 2013 |